Mrmainstreet, JT could launch an AG and immediately reduce Hikma sales by 50%. For some reason, JT and team don’t feel this option is necessary yet. Why? I don’t know but the AG is the poison pill solution if the current strategy doesn’t pan out. Personally, I would like to see an immediate AG launch and an injunction request from AMRN. I’m pretty sure both are coming. I think the evidence of scripts being switched and the formulary tier changes for Vascepa is the evidence AMRN are gathering for injunctive relief for an irreparable harm claim. IMO.
News 
Market Data 
Discover 
AI
